Insider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Purchases 80,000 Shares of Stock

Nanalysis Scientific Corp. (CVE:NSCIGet Free Report) Director Michal Okoniewski acquired 80,000 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average price of C$0.38 per share, for a total transaction of C$30,400.00.

Nanalysis Scientific Price Performance

CVE NSCI opened at C$0.38 on Wednesday. The company’s 50 day simple moving average is C$0.47 and its 200 day simple moving average is C$0.45. The firm has a market capitalization of C$38.54 million, a PE ratio of -2.24 and a beta of 0.82. Nanalysis Scientific Corp. has a 12 month low of C$0.35 and a 12 month high of C$0.68. The company has a debt-to-equity ratio of 71.36, a current ratio of 1.52 and a quick ratio of 1.11.

About Nanalysis Scientific

(Get Free Report)

Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies.

See Also

Receive News & Ratings for Nanalysis Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanalysis Scientific and related companies with MarketBeat.com's FREE daily email newsletter.